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ABSTRACT
Purpose: We have established a prospective cohort of
1959 patients with chronic Chagas cardiomyopathy to
evaluate if a clinical prediction rule based on ECG, brain
natriuretic peptide (BNP) levels, and other biomarkers
can be useful in clinical practice. This paper outlines the
study and baseline characteristics of the participants.
Participants: The study is being conducted in 21
municipalities of the northern part of Minas Gerais State
in Brazil, and includes a follow-up of 2 years. The
baseline evaluation included collection of
sociodemographic information, social determinants of
health, health-related behaviours, comorbidities,
medicines in use, history of previous treatment for
Chagas disease, functional class, quality of life, blood
sample collection, and ECG. Patients were mostly
female, aged 50–74 years, with low family income and
educational level, with known Chagas disease for
>10 years; 46% presented with functional class >II.
Previous use of benznidazole was reported by 25.2%
and permanent use of pacemaker by 6.2%. Almost half
of the patients presented with high blood cholesterol
and hypertension, and one-third of them had diabetes
mellitus. N-terminal of the prohormone BNP (NT-
ProBNP) level was >300 pg/mL in 30% of the sample.
Findings to date: Clinical and laboratory markers
predictive of severe and progressive Chagas disease were
identified as high NT-ProBNP levels, as well as
symptoms of advanced heart failure. These results
confirm the important residual morbidity of Chagas
disease in the remote areas, thus supporting political
decisions that should prioritise in addition to
epidemiological surveillance the medical treatment of
chronic Chagas cardiomyopathy in the coming years. The
São Paulo-Minas Gerais Tropical Medicine Research
Center (SaMi-Trop) represents a major challenge for
focused research in neglected diseases, with knowledge
that can be applied in primary healthcare.
Future plans:We will continue following this patients’
cohort to provide relevant information about the
development and progression of Chagas disease in
remotes areas, with social and economic inequalities.
Trial registration number: NCT02646943; Pre-results.
INTRODUCTION
Chagas disease, which is caused by the proto-
zoan parasite Trypanosoma cruzi, remains one
of the most neglected diseases in the world,
with 8–10 million infected people. The most
important consequence of Chagas disease is
chronic Chagas cardiomyopathy, which
occurs in 20–40% of infected persons,1–4
with an incidence rate of 1.85% person-year.4
Chronic Chagas cardiomyopathy comprises
a wide range of manifestations, including
heart failure, arrhythmias, heart blocks,
sudden death, thromboembolism, and
Strengths and limitations of this study
▪ In this large multicentre cohort of patients with
Chagas cardiomyopathy previous use of benzni-
dazole was reported by one quarter of the
patients.
▪ Clinical and laboratory markers predictive of
severe and progressive Chagas disease (ChD)
were identified in the São Paulo-Minas Gerais
Tropical Medicine Research Center (SaMi-Trop)
cohort, as high N-terminal of the prohormone
BNP (NT-ProBNP) levels, as well as symptoms
of advanced heart failure.
▪ Results presented in this paper confirm the
important residual morbidity of ChD in remote
areas, thus supporting political decisions that
should prioritise in addition to epidemiological
surveillance the medical treatment of CCC in the
coming years.
▪ The SaMi-Trop cohort represents a major chal-
lenge for focused research in neglected diseases,
with knowledge that can be applied in primary
health care.
▪ One weakness is the lack of baseline echocardio-
grams, which could help in the clinical stratifica-
tion of patients. However, this information is
being collected in the second follow-up visit.
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stroke.5 Clinical presentation typically varies widely
according to the degree of myocardial damage, and most
patients present a mild form of heart disease frequently
characterised only by the presence of asymptomatic
abnormalities on the ECG or in other complimentary
examinations.6 The Brazilian Consensus of Chagas
disease defines Chagas cardiomyopathy as the presence
of typical ECG abnormalities in patients with a positive
serological test for T. cruzi infection.7 When heart failure
and/or severe arrhythmias manifest, the prognosis is
ominous, with high and premature mortality rates in
adult male patients,8 as well as in the elderly.9 Indeed,
when compared with patients with idiopathic cardiomy-
opathy, patients with chronic Chagas cardiomyopathy
have poorer survival, irrespective of other clinical and
echocardiographic parameters.10
Chronic Chagas cardiomyopathy is a potentially lethal
condition, but the severity of the disease varies widely and
accurate stratification of the risk of disease progression
and death remains an unsolved challenge.5 Risk scores
have been developed,11–13 including a validated one.11
However, current risk scores rely on the availability of
several diagnostic tests, including Holter monitoring, stress
testing, echocardiographic examination and chest X-ray,11
or special examinations such as signal averaged ECG.12 13
These methods are not readily available in the rural
endemic areas and have a limited role in risk stratification
in the primary care setting. Indeed, a simple, low-cost and
easy-to-use prognostic model suitable for the primary care
setting is lacking. Although some promising studies show
the potential value of some new biomarkers,14 15 the lack
of validated and easily available biomarkers for active infec-
tion or clinical end points are a problem for assessing the
performance of new drugs or therapeutic interventions.
In addition, given the lack of a health service structure,
mainly in remote areas, along with the low levels of aware-
ness among healthcare providers, cases of chronic Chagas
cardiomyopathy are under-recognised and undertreated.
Seeking to contribute to the knowledge of Chagas
disease, a large cohort of patients with chronic Chagas
cardiomyopathy was established in Minas Gerais State
(Brazil). This cohort aims to develop a prognostic algo-
rithm—based on simple ECG measurements in conjunc-
tion with clinical information and brain natriuretic peptide
(BNP) levels—that would be used to predict the risk of
disease progression and death in patients with chronic
Chagas cardiomyopathy and be useful in the clinical man-
agement of such patients. This paper outlines the study
and baseline characteristics of the cohort participants.
COHORT DESCRIPTION
The São Paulo-Minas Gerais Tropical Medicine Research
Center (SaMi-Trop) consists of a network of collaborat-
ing scientists in the States of Minas Gerais and São Paulo
which has been established for the purpose of develop-
ing and conducting research projects on Chagas disease.
The SaMi-Trop project is a prospective cohort study with
at least 2 years of follow-up, including one visit at base-
line and another at 24 months. The cohort of patients
with chronic Chagas cardiomyopathy was established
by using patients under the care of the Telehealth
Network of Minas Gerais, a programme designed to
support primary care in Minas Gerais State, Brazil.16 In
this programme, all patients’ ECG and clinical data are
sent to a central reading unit centre that also collects
clinical data such as the history of Chagas disease.
Using this database, we selected 21 municipalities
within a limited region in the northern part of the
State of Minas Gerais where the prevalence of patients
with chronic Chagas cardiomyopathy was expected to
be high (figure 1).
Eligible patients were selected based on the ECG
results performed in 2011–2012 by the Telehealth
Network, which from now on will be called index ECG.
Only patients who fulfilled all of the following inclusion
criteria were selected: (1) self-reported Chagas disease;
(2) presence of the following abnormalities on the
index ECG:17 possible old myocardial infarction (major
Q wave abnormalities or minor Q waves abnormalities
with ST segment or T wave abnormalities), complete
intraventricular block (right, left or unspecified), fre-
quent supraventricular or ventricular premature beats,
major isolated ST segment or T wave abnormalities,
atrial fibrillation or flutter or supraventricular tachycar-
dia or other major arrhythmias, major atrioventricular
conduction abnormalities or pacemaker use, or major
QT prolongation (QT index >115%), left or right ven-
tricular hypertrophy and (3) aged 19 years or more. The
exclusion criteria included pregnancy or breast feeding,
and any life-threatening disease with an ominous prog-
nosis that suggested a life expectancy of <2 years.
The simple size was calculated considering the minimal
number of events per variable acceptable in a propor-
tional hazards regression analysis of 10 events per vari-
able.18 As the prediction model has to be developed and
validated, and the whole sample will be divided into two,
the number of events should be 200. For a 2-year
follow-up period and annual mortality rate of 5% in
chronic Chagas cardiomyopathy (10% in 2 years), the cal-
culated sample size was 2000 participants.
All eligible participants were tested for the presence of
anti-T. cruzi antibodies using chemiluminescent micro-
particle immunoassay. Negative results were confirmed
by two other enzyme immunoassay (EIA) presenting dif-
ferent antigens. The final cohort consists of patients
confirmed to be seropositive. The patients’ distribution
by municipalities and the distance from the reference
centre in health is presented in table 1.
The cohort will be followed for 2 years, until primary
outcome or loss to follow-up. The primary outcome is
death and the secondary outcomes are changes in the
ECG pattern and hospitalisation due to cardiovascular
complications. Ascertainment of the occurrence of
deaths will be done using the National Mortality
Information System (SIM) from the Ministry of Health.
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Table 2 summarises the types of data collected at
baseline and of those that will be collected at the
2-year follow-up visit. All eligible participants were
recruited by the family health programme team. The
baseline visit was performed at public health primary
care units by previously trained staff. The patients were
interviewed using a standardised questionnaire, and
had a blood sample collected and an ECG evaluation.
The data were collected electronically and sent to the
data centre at the University of São Paulo via a web-
based system.
A resting 12-lead ECG was recorded using an ECG PC
machine (TEB, São Paulo, Brazil). The ECG recordings
were sent electronically to the Telehealth system and read
by a trained cardiologist; the written report was subse-
quently returned to the patient’s physician. For research
purposes, ECGs were also automatically analysed using
the University of Glasgow ECG analysis programme
(release 28.5, issued on January 2014) and reviewed by
trained cardiologists to ensure quality control. ECGs will
be classified using the Minnesota Code criteria using vari-
ables derived from the median complex of the Glasgow
University software measurement matrix.22
Blood was collected into serum-separating tubes, and
allowed to clot at room temperature for 30 min. The
serum was centrifuged at 1300 g for 10 min at room tem-
perature. This was then subjected to storage at −20°C
and later shipped with dry ice to the central laboratory
in São Paulo.
Brazilian Mortality Information (SIM) data will be
used to ascertain patients’ vital status after the follow-up
period as well as the underlying causes of death, which
are coded under the International Classification of
Disease, 10th Revision (ICD-10).
Figure 1 Geographical location
of the 21 municipalities included
in the São Paulo-Minas Gerais
Tropical Medicine Research
Center (SaMi-Trop) project. Minas
Gerais, Brazil.
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In this paper, a descriptive analysis of the baseline
characteristics of the cohort participants was done using
frequency and percentage distribution. SPSS V.19 (SPSS
Inc, IBM, Armonk, New York, USA) and ArcView, V.10.1
(Environmental Systems Research Institute Inc, http://
www.esri.com/software/arcview/) were used.
This cohort study is a component of a larger study to
evaluate biomarkers of Chagas disease sponsored by a
grant from National Institute of Allergy and Infectious
Diseases (NIAID)/National Institutes of Health (NIH)
Neglected Tropical Disease Centre.
CHARACTERISTICS OF THE STUDY POPULATION
Of the 55 480 ECGs performed in the 21 selected muni-
cipalities from 2011 to 2012, a total of 4689 patients
were eligible for the study, and 2157 were located and
completed the baseline assessment in 2013–2014. In
comparison to the eligible group, the participants had a
higher percentage of women (67.1% vs 59.9%, p<0.01)
and were younger (59.5 vs 60.7 years, p<0.01). The final
cohort consists of 1959 (90.8%) participants confirmed
to be seropositive for Chagas disease (figure 2).
Table 3 shows the main sociodemographic character-
istics, socioeconomic categories and self-perception of
health of study participants at baseline. Most patients
were female (67.5%), aged between 50 and 74 years
(62.6%), sharing the same household with two other
people or less (56.6%), and had a family monthly
income of US$327. The educational level was very low
with 38.7% having had between 1 and 4 years of school,
and 34.4% never having attended school. Cohort
members self-reported their health status as average
(57.7%) or good (25.8%).
The majority of the patients self-reported that they
have had Chagas disease for over 10 years, and that they
had at least one family member with a history of Chagas
disease. Based on the New York Heart Association
(NYHA) Functional Classification, 45.9% of the patients
were classified as level II or more (ie, have symptoms of
heart failure). Among Chagas disease patients in the
cohort, 6.2% reported permanent use of a pacemaker.
Previous treatment for Chagas disease was reported by
51.6% of Chagas disease patients (25.2%), including 492
who reported previous treatment with benznidazole.
The N-terminal of the prohormone BNP (NT-ProBNP)
level was >300 pg/mL in 30% of the sample (table 4).
As seen in table 5, the prevalence of one or more self-
reported comorbid conditions at baseline was high, includ-
ing high serum cholesterol (40.1%), hypertension
(36.0%), diabetes mellitus (10.1%), thyroid disorder
(8.1%), and kidney disease (7.3%). Leishmaniasis was
reported by 22 patients (1.2%). Only 22.3% of patients
Table 1 Distribution of patients including in São
Paulo-Minas Gerais Tropical Medicine Research Center
(SaMi-Trop) cohort according to the municipality and
distance to the reference centre, Montes Claros (n=1959)
Municipalities Number Per cent Distance (km)
São Francisco 325 16.6 163
Carbonita 202 10.3 203
Minas Novas 164 8.4 289
Janaúba 166 8.5 134
Turmalina 131 6.7 264
Bocaiúva 128 6.5 47
Chapada do Norte 122 6.2 295
Berilo 113 5.8 333
Porteirinha 71 3.6 170
Brasília de Minas 71 3.6 105
Fruta de Leite 68 3.5 186
Claro dos Poções 62 3.2 79.5
Verdelândia 69 3.5 173
Pai Pedro 56 2.9 185
Ubaí 54 2.8 153
Leme do Prado 42 2.1 273
Francisco Sá 38 1.9 52
Rio Pardo de Minas 28 1.4 276
Jenipapo de Minas 19 1.0 369
Francisco Badaró 16 0.8 347
Monte Azul 14 0.7 244
Total 1959 100.0 –
Table 2 Measurements obtained at different phases of
the SaMi-Trop study
Phase Measurements
Baseline: 2013–
2014
Questionnaires with sociodemographic
information, social determinants of
health, health-related behaviours
(smoking, alcohol consumption and
physical activity), self-reported
comorbidities, medication use, history of
previous treatment for Chagas disease,
signs and symptoms, functional class
(Cardiovascular Functional Class
Scale)19 and quality of life
(WHO-QOL-BREF)20
ECG
Blood collection: immunoassays, PCR
for T. cruzi, NT-ProBNP
Follow-up:
2015–2016
Questionnaires with sociodemographic
information, social determinants of
health, health-related behaviours,
self-reported comorbidities, medication
use, signs and symptoms since
baseline. Functional class and quality of
life
Vital status, history of health service
utilisation, including hospital
admissiona, health literacy (Short
Assessment of Health Literacy)21
ECG
Echocardiogram
Blood collection: NT-ProBNP
NT-ProBNP, N-terminal of the prohormone brain natriuretic
peptide; SaMi-Trop, São Paulo-Minas Gerais Tropical Medicine
Research Center; T. cruzi, Trypanosoma cruzi; WHO-QOL-BREF,
WHO Quality of Life-BREF.
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reported having performed any physical activity during the
prior week, 16.2% reported having drunk alcohol in the
previous month, and 7.3% reported that they were current
smokers. In terms of medications, 36.4% of patients
reported the current use of one or two medicines, while
30.1% reported no current use of any medication. The
most common medicines being used were diuretics
(49.1%), ACE (28.6%), angiotensin receptor blockers
(ARBs) (28.4%), aspirin (26.2%), and amiodarone (22%).
Considering the fact that almost half of the patients
were in functional class II or more, with 30% with BNP
levels higher than 300 units/L, there is an overall low
usage of the recommended drugs for heart failure, par-
ticularly of β-blockers. This may explain at least in part
the high frequency of cardiac symptoms reported:
63.5% had racing heartbeat, 62.5% had prolonged faint-
ing spells or dizziness, 61.3% had an abnormal ECG,
61.0% had heart palpitations, and 59.4% had shortness
of breath at exercises. The relative high frequency of
amiodarone use may be related to the high frequency of
cardiac arrhythmias in chronic Chagas cardiomyopathy,
as well as the established practice, in Brazil, to prescribe
amiodarone to prevent sudden death.
FINDINGS TO DATE
Clinical and laboratory markers predictive of severe and
progressive Chagas disease were identified in SaMi-Trop
cohort, as high NT-ProBNP levels, as well as symptoms of
advanced heart failure. The NT-ProBNP level was
>300 pg/mL in 30% of the sample. High circulating levels
of natriuretic peptides are related to the presence of left
ventricular dysfunction23 and a higher risk of death.24
Among Chagas disease patients in the cohort, 6.2%
reported permanent use of a pacemaker. This percent-
age is far below the 14.0% found in another recently
published Brazilian cohort study of patients with Chagas
disease.25 However, Chagas disease is still a major cause
of use of pacemakers and defibrillators in Brazil, surpass-
ing the indications due to coronary artery disease in
some regions. The literature too point out the underuse
of this device in Brazil when compared with other coun-
tries,26 which is unfortunately what we expected to find
in the remote regions represented in the current study.
In this large multicentre cohort, previous use of benzni-
dazole was reported by one-fourth of the patients. It is well
known that the persistence of T. cruzi is directly related in
the pathology of the chronic phase, but it remains to be
proved that parasite load reduction by trypanocidal treat-
ment leads to concomitant attenuation of cardiomyop-
athy.2 25 In the recently released BENEFIT trial,25 that
included Brazilian patients, treatment with benznidazole
did not significantly reduce cardiac clinical deterioration
in the 5 years of follow-up in Chagas cardiomyopathy.
Although T. cruzi infection does not have a sexual pre-
dilection,27 studies show higher prevalence among
women.28 29 This difference may be related to frequent
use of health services by women, even after controlling
for restrictions in routine activities due to health
reasons30 as well as greater availability to participate in sci-
entific studies, especially those with a longitudinal com-
ponent such as in this investigation.
Results presented in this paper confirm the important
residual morbidity of Chagas disease in the remote areas,
thus supporting political decisions that should prioritise
in addition to conducting epidemiological surveillance of
the medical treatment for chronic Chagas cardiomyop-
athy in the coming years. The SaMi-Trop cohort repre-
sents a major challenge for focused research in neglected
diseases, with knowledge that can be applied in primary
healthcare. The study has the potential to provide rele-
vant information about the development and progression
of Chagas disease in remote areas with social and eco-
nomic inequalities.
Figure 2 The SaMi-Trop project diagram. ChD, Chagas disease; EIA, enzyme immunoassay; NT-ProBNP, N-terminal of the
prohormone brain natriuretic peptide; SaMi-Trop, São Paulo-Minas Gerais Tropical Medicine Research Center.
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STRENGTHS AND LIMITATIONS
The SaMi-Trop is one of the largest multicentre cohort
study of Chagas disease conducted in the world. It has
the potential of identifying biomarkers that will be
used to predict the risk of disease progression and
death, as well as permit comparative analysis with
other similar cohorts. Most studies that evaluated bio-
markers in Chagas disease had a cross-sectional design.
The large number of patients included in this investi-
gation is outstanding, especially in a rural and dis-
persed area. Our preliminary results confirmed the
important residual morbidity of Chagas disease in such
remote areas and found that these patients are cur-
rently being undertreated. We hope that our findings
will guide political decisions aiming at enhancing
access to healthcare of Chagas disease patients in the
coming years.
Second, the SaMi-Trop cohort represents a major chal-
lenge for focused research in neglected diseases, with
knowledge that can be applied in primary healthcare.
The study has the potential to provide relevant informa-
tion about the development and progression of Chagas
disease in remote areas with social and economic
inequalities. As pointed out by Maguire,31 there is an
urgent need for a new strategy for Chagas disease treat-
ment and studies for evaluation of results because the
infected patients are ageing and have only a few years
left to live.
One weakness of the study is that no data on weight
and height in the health services indicators were
included at the baseline. Another important limitation is
the lack of baseline echocardiograms, which could help
in the clinical stratification of patients. All this informa-
tion is being collected in the second follow-up visit. As
the focus was to find biomarkers related to the cardiac
outcome and given the budgetary limitations, no
Table 3 Sociodemographic characteristics of SaMi-Trop
cohort members (n=1959)
Variables N Per cent
Sex
Female 1.323 67.5
Male 636 32.5
Age
<50 years 499 25.6
50–74 years 1.223 62.6
>74 years 231 11.8
Number of household members
1–3 1.106 56.6
4–6 709 36.3
7–17 138 7.1
Family monthly income data
>US$327 1.037 53.1
≤US$327 916 46.9
Skin colour
Mixed 1.144 58.6
White 426 21.8
Black 348 17.8
Others 32 1.8
Years of school
1–4 year 862 44.2
Illiterate 670 34.4
5–8 years 320 16.4
Other 98 5.0
Marital status
Married or living with partner 1.238 63.4
Widower 449 23.0
Single 176 9.0
Divorced 90 4.6
Self-perception of health
Very good 57 2.9
Good 499 25.8
Average 1.116 57.7
Bad or very bad 264 13.6
Small differences in total N for each variable are due to missing
values.
Others in Skin colours include Asians (27) and Native Americans
(5).
Others in Educational level included: elementary school (81) and
graduate school (17).
Dollar quotation from July 2013.
Table 4 Distribution of patients according to self-reported
Chagas disease, cardiovascular functional class and
NT-ProBNP results in the SaMi-Trop study
Variables
Valid
N N
Per
cent
Chagas disease self-reported 1.955
Yes 1870 95.6
No 64 3.3
No response 21 1.1
Duration of Chagas disease
(years)
1.896
>10 1179 62.2
1–10 695 36.6
<1 22 1.2
Chagas disease in another
family member
1.947
Yes 1384 71.1
No 384 19.7
Do not know 179 9.2
Previous treatment for Chagas
disease
1.953
Yes 1008 51.6
No 873 44.7
Do not know 72 3.7
Previous use of benznidazole
medicine
1.955
No 1320 67.5
Yes 492 25.2
Do not know 143 7.3
NYHA Functional Classification 1.931
I 1059 54.8
II or more 872 45.2
NT-ProBNP level, pg/mL 1.955
<300 1368 70.2
≥300 581 29.8
NT-ProBNP, N-terminal of the prohormone brain natriuretic
peptide; NYHA, New York Heart Association.
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indeterminate form or negative controls were included
in this cohort; this will preclude the study of the early
biomarkers of disease progression. However, Chagas
disease is mostly a disease of adults and older age
groups in countries where the vectorial transmission was
interrupted and this cohort provides a unique opportun-
ity for recognising predictors of higher risk using simple
biomarkers in a community sample of patients with
Chagas cardiomyopathy.
COLLABORATIONS
Collaborations in data analysis will be welcome through
specific research proposals sent to individual SaMi-Trop
investigators. Exchange of doctoral or postdoctoral
fellows is very welcome.
The data set will be open access for two years at the
end of the data collection process (August 2018). In the
meantime, applications to use the data should be made
by contacting the researchers of the SaMi-Trop cohort
Table 5 Prevalence of comorbid conditions, selected behavioural characteristics, medications used, signs and symptoms,
and self-reported health in the SaMi-Trop cohort.
Variables Valid N N Per cent
Comorbid conditions 1.959
High serum cholesterol 785 40.1
Hypertension 706 36.0
Diabetes mellitus 198 10.1
Thyroid disorder 159 8.1
Kidney disease 143 7.3
Leishmaniosis 22 1.2
Behavioural characteristics 1.945
Physical activity last week (minimal 30 min) 434 22.3
Alcohol last month 318 16.2
Current smoking 143 7.3
Number of medicine in use 1.959
0 589 30.1
1–2 714 36.4
3–4 538 27.5
≥5 118 6.0
Medicine in use (yes) 1.940
Diuretics 951 49.1
ACE 553 28.6
ARBs 550 28.4
Aspirin 507 26.2
Amiodarone 429 22.0
Carvedilol 380 19.6
Digoxin 140 7.2
β-blockers 140 7.2
Vasodilators 84 4.3
Warfarin 11 0.6
Signs and symptoms or self-reported conditions (yes) 1.924
Heartbeat racing or beating abnormally 1.222 63.5
Prolonged faintness or dizziness 1.203 62.5
Problems on ECG 1.180 61.3
Heart palpitations 1.174 61.0
Short of breath during physical exercises 1.143 59.4
Heartbeat racing at rest 1.015 52.8
Heartbeat not regular 902 46.9
Difficulty breathing when lying down 752 39.1
Unable to climb two flights of stairs 749 38.9
Awake during the night unable to breath 683 35.5
Trouble swallowing 599 31.1
Swelling or puffiness of the feet in the morning 502 26.1
No bowel movement for three or more days 478 24.8
Fainting or loss of consciousness 429 22.0
Visible neck veins when standing up or sitting 409 21.3
Pain when swallowing food 342 17.8
Pacemaker 110 6.2
Megaesophagus 117 6.1
ARBs, angiotensin receptor blockers; SaMi-Trop, São Paulo-Minas Gerais Tropical Medicine Research Center.
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and filling in the application form. The questionnaires
and interviewer guides of the baseline will also be avail-
able in electronic formats at http://www.ufsj.edu.br/
tecnologiasemsaude_pesquisa/projetos.php.
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